Document:

<PAGE>

                                                                   EXHIBIT 10.20

                             DEVELOPMENT AGREEMENT

     THIS AGREEMENT, effective as of April 5, 1999 ("Effective Date") by and
among Esperion AB, a corporation organized under the laws of Sweden having a
principal place of business at Ekensbergsvagen 115, 17141 Solna, Sweden
("ESPERION")

                                      AND

OctoPlus b.v., a company organized under the laws of The Netherlands having a
principal place of business at Niels Bohrweg 11-13, 2333 CA Leiden, The
Netherlands ("OCTOPLUS").

Background

ESPERION's parent company, Esperion Therapeutics Inc., has granted ESPERION a
right to use all the rights acquired from Pharmacia AB of Active Ingredient (as
hereinafter defined) and the rights to use compound for the Project (as
hereinafter defined).

ESPERION and Esperion Therapeutics Inc. have successfully conducted first
development studies on Active Ingredient (as hereinafter defined) based on a
lipid formulation, the results of which shall be a basis for further
development.

OCTOPLUS has experience in the development of pharmaceutical products containing
compounds of biotechnological origin such as peptides, proteins and genes,
including but not limited to formulation development, analytical services and
stability testing..

OCTOPLUS and ESPERION wish to undertake a cooperative program aimed at
developing a parenteral formulation with Active Ingredient (as hereinafter
defined) which shall result in the supply of toxicology and clinical samples to
be investigated for cholesterol removal therapy.

     NOW THEREFORE, in consideration of the premises and mutual covenants and
conditions set forth herein, the Parties agree as follows:

                                   ARTICLE I
                                  Definitions

1.01  When used in this Agreement, each of the following terms shall have the
meanings set out in this Article I.

                                       1
<PAGE>

1.02  "Active Ingredient" means the recombinant Apo-Al Milano protein in bulk
       -----------------
ready to be used for the manufacturing of the Formulation (as hereinafter
defined).

1.03  "Affiliate" means any entity, which controls, is controlled by, or is
       ---------
under common control of a Party.

1.03.1  For purposes of this definition, a Party shall be deemed to control
another entity

1.03.1.1. If it owns or controls, directly or indirectly, at least fifty percent
(50%) of the voting equity of such other entity (or other comparable ownership
interest for an entity other than a corporation) or

1.03.1.2. if it has management control of the other entity.

1.03.1.2. Any reference in this Agreement to either Party shall include its
Affiliates (unless the context requires otherwise).

1.04  "ESPERION Patent" means, collectively, any Patents and patent applications
       ---------------
owned or controlled by ESPERION, and any international counterparts thereof,
covering Active Ingredient its production and/or its pharmaceutical use, which
can be used to develop and produce parenteral formulation of Formulation and
which legally are at the disposal of ESPERION.

1.05  "Calendar Quarter" shall mean the Calendar Quarters of the year beginning
       ----------------
first of January, April, July and October.

1.06  "Clinical Samples" mean any parenteral formulation made by OCTOPLUS
      ------------------
according to GMP and supplied to ESPERION, or a sublicensee thereof, which meet
the clinical Specifications mutually agreed upon by the Parties prior to release
to ESPERION and/or such licensee for purpose of evaluation by ESPERION or its
sublicensee in a clinical study. ESPERION shall be responsible for the release
of Clinical Samples according to the Quality Assurance Functions (ANNEX E).

1.07  "Commercially Reasonable Best Efforts" means those efforts employed by the
       ------------------------------------
Parties, equivalent to that level of attention and care and providing of funding
and manpower that they devote to their other businesses and products which will
at least reach a standard normal for comparable businesses/research entities.

1.08  "Development Work" means the services carried out by OCTOPLUS to result in
      ------------------
the manufacturing and supply of Clinical Samples according to the
Specifications.

                                       2
<PAGE>

1.09  "ESPERION Know how" means information of ESPERION regarding the research
       -----------------
and development of the Active Ingredient.

1.10  "Formulation" means a parenteral formulation with Active Ingredient.
       -----------

1.11  "Indication" means the treatment of hypercholesterol blood levels in
       ----------
humans.

1.12  "Know How" means all information concerning Active Ingredient and
       --------
parenteral formulation developed under this Agreement.

1.13  "OCTOPLUS Know How" means information of OCTOPLUS regarding the general
       -----------------
development and manufacture of parenteral formulations and related technologies.

1.14  "Party" shall mean a Party of this Agreement.
       -----

1.15  "Project" means a development program to be conducted by ESPERLON and
       -------
OCTOPLUS according to the Project Plan aimed at developing and manufacturing
parenteral formulations for clinical trials.

1.16  "Project Group".  The Project Group shall mean the committee to be formed
       -------------
pursuant to Article IV.

1.17  "Project Plan" shall be a cooperative undertaking for conducting the
       ------------
development of the Formulation and manufacturing and supply of Clinical Samples.
The framework of the Project Plan is described in ANNEX A and it may be
supplemented or amended from time to time by mutual agreement.

1.18  "Quality Assurance Functions" means a list of functions which shall apply
       ---------------------------
in the case Clinical Samples are manufactured by OCTOPLUS and supplied to
ESPERION, attached hereto as an ANNEX E.

1.19  "Report" means the final report to ESPERJON containing OCTOPLUS' results
       ------
of OCTOPLUS' Development Work for a parenteral formulation which can be utilized
to set up a program for a manufacturing dossier necessary for the registration
dossier in the EEC.

1.20  "Specifications" means the written specifications developed by the Project
       --------------
Group for the raw materials and for the manufacturing and quality control of the
parenteral formulation, and any and all additions and amendments to the same
made by the written agreement of the Parties during the term of this Agreement.
The Specifications of the parenteral formulation will be attached to and made a
part of this Agreement as ANNEX C.

1.21  "Sublicensee" means a Party whom ESPERION has sublicensed its license(s)
       -----------
granted hereunder.

                                       3
<PAGE>

1.22  "Time Period" means the time within which OCTOPLUS shall finalize the
       -----------
Project as described in ANNEX B. .

1.23  "Toxicology Samples" means any parenteral formulation made by OCTOPLUS
      --------------------
according to GMP and supplied to ESPERION, or a sublicensee thereof, which meet
the Specifications mutually agreed upon by the Parties prior to release to
ESPERION and/or such licensee for purpose of evaluation by ESPERION or its
sublicensee in a toxicology study.  ESPERION shall be responsible for the
release of Toxicology Samples according to the Quality Assurance Functions
(ANNEX E).

                                   ARTICLE II
                            Contribution of OCTOPLUS

2.01  OCTOPLUS Services.  OCTOPLUS shall conduct certain studies and tasks as
      -----------------
set forth in the Project Plan.  OCTOPLUS shall use its Commercially Reasonable
Best Efforts to provide the services necessary to fulfil the Project within the
Time Period.  In case of additional work which could not be foreseen in the
Project Plan and which has been approved by the Project Group OCTOPLUS shall be
entitled to perform and request a remuneration of such additional work according
to Article V.

2.02  Report.  The Development Work shall culminate in the Report as a summary
      ------
and documentation of the Development Work.
2.02.1.  OCTOPLUS shall use Commercially Reasonable Best Efforts to present the
Report to ESPERION within two months after the Formulation has been delivered to
ESPERION.

2.02.2.  If OCTOPLUS determines at any time during the term of this Agreement
that the Report cannot be delivered on schedule due to whatever reasons,
OCTOPLUS shall promptly notify ESPERION.

2.02.3.  OCTOPLUS shall use its Commercially Reasonable Best Efforts to deliver
the Report after an extension period of not more than two months.

2.02.4.  In the event that Report cannot be delivered after the extension period
has elapsed, ESPERION may terminate this Agreement within a period of 14
(fourteen) calendar days after the extended deadline has passed.  The foregoing
shall not apply if

                1) ESPERION has agreed to a revised date or
                2) if the delay is caused on events outside the control of
                OCTOPLUS;
                in this case, the period will be extended accordingly

                                       4
<PAGE>

2.03  Samples of Formulation.  OCTOPLUS shall supply ESPERION with
      ----------------------
investigational samples and clinical samples and prototypes developed under this
Agreement at no cost other than the compensation as provided for in Article V.

2.03.1.  OCTOPLUS' S Compliance with Specifications.  OCTOPLUS warrants that all
         ------------------------------------------
OCTOPLUS'S Toxicology and Clinical Samples delivered under this Agreement shall
conform to the Specifications.

2.03.2.  GMP for Clinical Samples.  In the event that Clinical Samples will be
         ------------------------
used by ESPERION trials in humans, OCTOPLUS shall employ current Good
Manufacturing Practices (GMP) in the production of such Clinical Samples,
including additions and amendments to such GMP regulations during the term of
this Agreement, and shall comply with all other statutes and regulations
applicable to it.

2.04  Quality Control.  Each shipment of OCTOPLUS's clinical samples shall be
      ---------------
accompanied by quality control certificates for each batch as described in the
Specifications.  If not set forth explicitly otherwise, OCTOPLUS shall not be
obliged to provide any additional quality control with regard to OCTOPLUS's
clinical samples.

2.05  Audit at OCTOPLUS.  OCTOPLUS will permit an authorized representative of
      -----------------
ESPERION or its Affiliates to inspect at all reasonable times the process of
manufacture and storage of the Clinical Samples under such conditions as
OCTOPLUS may reasonably require in order to protect the confidentiality of its
and its other customer's proprietary and confidential information.  ESPERION
shall announce such audit at least one month in advance to OCTOPLUS.

                                  ARTICLE III
                            Contributions of ESPERION

3.01  ESPERION Cooperation.  ESPERION shall use its best efforts to duly
      --------------------
cooperate during the entire course of the Project.

3.02  Active Ingredients Supply.  ESPERION shall supply OCTOPLUS with such
      -------------------------
quantities of Active Ingredients at such times as OCTOPLUS reasonably, at its
discretion, needs for the Project at no-cost to OCTOPLUS.  Each shipment of
Active Ingredients shall be accompanied by quality control certificates and
safety data sheets for each batch.  All Active Ingredients supplied hereunder
shall be utilized by OCTOPLUS solely for conducting work on the Project.

3.03  ESPERION'S Sole Liability for ESPERION'S Active Ingredients. ESPERION
      -----------------------------------------------------------
shall, provided that the damage is not caused or under the control of OCTOPLUS,
solely be liable for any damages caused by

                                       5
<PAGE>

ESPERION Active Ingredients including damages of any raw materials, any
materials used for production and Clinical Samples.

3.04  ESPERION'S Compliance with Specifications.  ESPERION warrants that all
      -----------------------------------------
ESPERION'S Active Ingredients delivered under this Agreement shall conform to
the Specifications as the Parties have agreed upon.

3.05  GMP for Active Ingredients.  In the event that ESPERION Active Ingredients
      --------------------------
are used by OCTOPLUS in order to produce Clinical Samples for use in humans,
ESPERION shall employ current Good Manufacturing Practices (GMP) in the
production of Active Ingredients, including additions and amendments to such GMP
regulations during the term of this Agreement, and ESPERION shall comply with
all other statutes and regulations applicable to it and to the manufacture of
Active Ingredients.

3.06  Quality Control.  Each shipment of ESPERION'S Active Ingredients shall be
      ---------------
accompanied by necessary quality control certificates for each batch as
described in the Specifications.  If not explicitly set, forth otherwise,
OCTOPLUS shall not be obliged to provide any additional quality control with
regard to ESPERION'S Active Ingredients.

3.07  Active Ingredients Data of ESPERION.
      -----------------------------------
ESPERION shall supply OCTOPLUS with relevant data related to the Project as set
forth in ANNEX D and all other information OCTOPLUS might additionally require
in good faith to fulfil the Project.

3.08  Evaluating Results.  ESPERION shall duly evaluate the results in the
      ------------------
Report in order to promote the Project as much as practical.  If ESPERION does
not reprove such results in writing in detail within a definite period of forty
five (45) calendar days after presentation, the same shall be irrevocably deemed
to be finally approved.

3.09  Clinical Trials.  ESPERION shall in its sole discretion be responsible for
      ---------------
planning and carrying out all clinical trials of Formulations, and for preparing
the portions of the applicable regulatory documents which deal with the Active
Ingredients, and with the clinical trial reports.  ESPERION will own the results
of all clinical trials and all regulatory documents that ESPERION files for
registration and approval of Formulations.

                                   ARTICLE IV
                                  Project Group

4.01  Control over Project.  The Project Group shall have the primary control
      --------------------
over the direction and the course of the Project.  The Project Group shall
modify the Project Plan, and/or the Specifications as appropriate.  In this
sense "Project Group" means a group composed of one representative appointed by
ESPERION and one appointed by OCTOPLUS which shall

                                       6
<PAGE>

be responsible for planning and monitoring the Project to ensure diligent
completion thereof. The persons now appointed by the respective Party are:

OCTOPLUS b.v.                      ESPERIONAB
Dr Ewoud van Winden                Dr. Hans Ageland
Scientist Formulation Research     VP of Operations and Projects
Niels Bohr Weg 11 - 13             Svartviksslingan 114
2300 AS Leiden                     16739 Bromma
The Netherlands                    Sweden

4.02  Responsibility of the Project Group.  The Parties have expressed their
      -----------------------------------
mutual intention that the Project be promptly completed, and, to that end, it is
the responsibility of the Project Group to ensure that the Parties use their
reasonable best efforts, equivalent to the same level of attention and care they
devote to their other businesses and products.

4.03  Meetings.  The Project Group shall meet at least quarterly, as appropriate
      --------
also by teleconference or videoconference, to review the progress of the
Project, to establish the program for the next quarter and to confirm that the
Milestones, Project Plan and/or time schedule are correct and, if not, determine
what modifications to same are required.

4.04  Decisions.  All decisions, including consents, approvals, authorizations,
      ---------
directions or recommendations of the Project Group, shall be made by consensus
of the Project Group arrived at in meetings, including those held by
teleconference or videoconference method.  If consensus cannot be reached , the
representative of ESPERION shall have the casting voted In no case shall
ESPERION misuse its position to request additional Development Work from
OCTOPLUS which from technical and other, in the sole discretion of OCTOPLUS,
internal reasons are not possible to perform.

                                   ARTICLE V
                               Funding of Project

5.01  ESPERION Funding.
      ----------------

It shall be paid for as follows:

5.01.1.    Hourly Payment.  ESPERION shall compensate OCTOPLUS for all employee-
           --------------
hours, which OCTOPLUS spends on the Project at the rate of

               Dfl 250,- (two hundred twenty-five Dutch Gulders) or
               correspondingly in Euro, plus VAT, if applicable.

                                       7
<PAGE>

5.01.2.  OCTOPLUS shall verify and document the time devoted by OCTOPLUS's
employees to the Project, and will submit an accounting each quarter.

5.01.3.  OCTOPLUS will allocate employee-hours consistently with its historical
allocation practice.

5.02  Additional Payments.  ESPERION shall compensate the costs at cost price
      -------------------
and to a fair market price for manufacturing of Clinical and Toxicology Samples.

5.03  Payment Schedule.  ESPERION shall pay OCTOPLUS the amount provided for in
      ----------------
Section 5.01 in installments, each Installment to be paid quarterly in advance.

5.04  Installments.  The first installment will be paid 30 days after this
      ------------
Agreement is executed and shall be pro-rated to represent the portion of the
preceding quarter covered by the Agreement.

5.04.1. Initially, each installment will be either

           Dfl 250,000.-- (two hundred fifty thousand Dutch Guilders) or
           correspondingly in Euro, plus VAT, if applicable.

5.04.2. At the end of the second quarter after execution of this Agreement, and
at the end of alternate quarters thereafter, the accountings presented by
OCTOPLUS will be compared with ESPERION's payments. If the payments are in
excess, the excess will be credited to future expenses. If OCTOPLUS's
accountings are in excess, ESPERION shall pay the excess amount to OCTOPLUS
within 60 (sixty) days of the determination.

5.04.3. ESPERION may have OCTOPLUS's records of man-hours and their allocation
to the Project audited by an independent Certified Public Accountant or
chartered accountant reasonably acceptable to OCTOPLUS acting in confidence, at
reasonable intervals to audit same.

5.05  Invoices.  Invoices will be as mentioned above either in Dutch Guilders or
      --------
Euro and all payments to OCTOPLUS shall be made either in Dutch Guilders or
Euro.  Invoices will cover specific line items to identify individual costs.
ESPERION will have the right to audit any. necessary documents associated with
such invoices.

5.06  Increase of Remuneration.  Prices will be updated on an annual basis
      ------------------------
beginning January 1, 2000.  The adjustment factor will be the official National
Price Index Factor, as published by the Government of the Netherlands in the
month of December prior to the calendar year during which the price adjustment
will become effective, however, for the first update the index for April 1999
shall be the basis for the update.

                                       8
<PAGE>

5.07  Overdue payments.  Overdue payments and excess payments according to
      ----------------
Section 5.04.2 above shall accrue interest at the rate of 4 (four) per cent
above EURIBOR - European Interbank Offered Rate (three months) - as reported in
Het Financieel Dagblad on the first business day that any payments becomes
overdue, until made.

5.08  No Setoff.  ESPERION shall not be entitled to exercise any right of
      ---------
setoff, net-out or deduction, take any credit, or assert any other defense
arising out of any transaction unless and until ESPERION has obtained a final
and non-appealable judgement against OCTOPLUS in the amount asserted by
ESPERION.  However, ESPERION shall, if ESPERION has justifiable claim instead of
paying such an amount to OCTOPLUS transfer the amount to an escrow account.  The
amount put in escrow shall be paid to the Party entitled to the payment
according to a final and non-appealable judgement or by mutual agreement between
the Parties.

5.09  Expenses.  Each Party shall bear all of the expenses of its own
      --------
participation or related to its contribution or the performance of its
obligations under this Agreement unless provided for in this Agreement. In the
event of unforeseen or extraordinary expenses OCTOPLUS shall be entitled to
request an equitable allocation after such allocation is approved by the Project
Group.

                                   ARTICLE VI
                                   Inventions

6.01  Classification.  Any inventions developed under this Agreement, or any
      --------------
subsequently signed Agreement, shall be classified as ESPERION Know-How or
OCTOPLUS Know-How, or if patentable and patented, shall be classified as
ESPERION Patents or OCTOPLUS patents, or joint patents depending upon the
employer of the person(s) making the invention.

6.02  Sole Inventions.  Each Party may file for and own patents and patent
      ---------------
application covering inventions made by its respective employees, and any
compensation to an inventor under provisions of labor law shall be paid by the
employer of that inventor.

6.03  Joint Inventions.  Inventions made jointly by employees of ESPERION and
      ----------------
OCTOPLUS shall be owned jointly by ESPERION and OCTOPLUS. However, if patent
applications on such inventions may be filed and only one Party requests such
filing, the invention and Know How should be owned solely by such Party.  In
such case the patent shall be regarded as sole invention, according to Section
6.02., of the Party filing such patent.

6.04  Expenses.  If the Parties agree to file for and obtain patents on such
      --------
joint inventions, all expenses incurred therein shall be shared equally, except
that the employer of each inventor will pay the inventor's compensation.

                                       9
<PAGE>

6.05  Transfer.  If a patent is obtained on such a joint invention, by both
      --------
Parties, the Parties are, after giving the other Party a four weeks notice,
entitled to transfer its interest in such patent to a third party.  Within the
notice period the non-transfering Party shall have a veto right against such
transfer that should not be unreasonably used.  Such reasons include, but are
not limited to transfer of such patent rights to a competitor of the other
Party.

6.06  Use of Joint Inventions.
      -----------------------

6.06.1. In the event that ESPERION wants to use, develop, license or transfer a
joint invention held by both Parties within the field of the ESPERION Know How,
ESPERION shall be free to do so, without having to get the approval from
OCTOPLUS and without any obligation to pay any remuneration.

6.06.2. In the event that OCTOPLUS wants to use, develop, license or transfer a
joint invention held by both Parties within the field of the OCTOPLUS Know How,
OCTOPLUS shall be free to do so, without having to get the approval from
ESPERION and without any obligation to pay any remuneration.

6.07  Other Formulations.  Notwithstanding the foregoing, OCTOPLUS may
      ------------------
exclusively use inventions and Know-how outside the ESPERION Know-How for
projects and for other formulations concerning any active ingredients for any
indication and for toll manufacturing, including any formulations for parties
who are entitled to have same produced.

6.08  Specific OCTOPLUS Know-How.  In no case ESPERION shall be entitled to
      --------------------------
request any of OCTOPLUS' information concerning specific OCTOPLUS Know How
unless required for registration purposes. OCTOPLUS will be entitled to
communicate such information directly to the authorities without disclosing it
to ESPERION.

6.09  Needed License from OCTOPLUS.  OCTOPLUS also hereby grants to ESPERION an
      ----------------------------
additional non-exclusive royalty-free license under such OCTOPLUS Know How as
ESPERION needs and OCTOPLUS has the power to grant, in research, to develop,
sale, manufacture, transfer or license the Active Ingredient in the
Formulation..

6.10  Assignments and Sublicenses.  The licenses based on instructions and Know
      ---------------------------
How belonging to OCTOPLUS and granted pursuant to this Article if not specially
regulated above

6.10.1. to ESPERION by OCTOPLUS may be transferred, assigned or licensed by
ESPERION for research, development, sale manufacture, marketing or license of
the Active Ingredient in the Formulation.

                                       10
<PAGE>

6.10.2. ESPERION shall inform OCTQPLUS of any such license or transfer and if
OCTOPLUS so requests the party that ESPERION do transfer and sublicense to shall
enter into a confidentiality agreement reasonably and acceptable to both
Parties.

6.11  Assignment of this Agreement.  This Agreement is personal to the Parties
      ----------------------------
and except as expressively stated herein cannot be sublicensed or assigned by a
Party without the prior written authorization of the other Party.

                                   ARTICLE VII
                                Clinical Samples

7.01  Manufacturing of Clinical Samples.  OCTOPLUS may commission the
      ---------------------------------
manufacturing of Clinical Samples to. a third party approved by ESPERION.

7.02  Confidentiality.  OCTOPLUS has an obligation to secure that such a third
      ---------------
party will sign an undertaking of confidentiality in accordance with Article 8
below.

7.03  Audit at the Third Party.  OCTOPLUS shall also secure that ESPERION will
      ------------------------
be permitted by an authorized representative of ESPERION or its Affiliates to
inspect at all reasonable times the process or manufacture and storage of the
Clinical Samples under such conditions as the third party may reasonably require
in order to protect the confidentiality of ESPERION's proprietary and
confidential information.  These audits should be announced at least two months
in advance in order to allow the third party to plan its internal capacities to
such audit.  The costs and time devoted by third parties and OCTOPLUS personnel
for such audit shall be remunerated by separate invoice.

                                  ARTICLE VIII
                                 Confidentiality

8.01  Confidentiality of Information.  No Party to this Agreement, or any
      ------------------------------
subsequently signed Manufacturing Agreement, shall disclose to any third party
nor use for any purpose, other than the purpose of this Agreement, or any
subsequently signed Manufacturing Agreement, information or data received from a
Party under this Agreement, or any subsequently signed Manufacturing Agreement,
without prior written approval from the Party from whom the information or data
was received.

8.02  Exceptions.  The obligations of non-disclosure and non-use shall apply for
      ----------
a period often (10) years following the expiration or termination of this
Agreement, or any subsequently signed Manufacturing Agreement, but shall not
apply to any information or data which receiving Party can show by competent
proof:

                                       11
<PAGE>

(a)  is known to the public prior to disclosure hereunder;
(b)  becomes known to the public through no fault of the receiving Party;
(c)  was known to the receiving Party prior to disclosure under this Agreement,
     or any subsequently signed Manufacturing Agreement by the disclosing Party;
(d)  is disclosed to the receiving Party by a third party having a legal right
     to make such disclosure;
(e)  is reasonably required to be disclosed to further the purposes of this
     Agreement, or any subsequently signed Manufacturing Agreement, including to
     file for registration, to file patent applications, and to contract with
     third parties under an obligation of confidentiality to further the
     development of the Formulations;
(f)  in the case of OCTOPLUS, is related to the general field of preparation of
     formulations, as distinguished from the preparation of the Formulations;
(g)  in the event that OCTOPLUS, fails to supply ESPERION's requirements under
     the Manufacturing Agreement, is reasonably required to be disclosed to a
     third party in order to secure the manufacture of ESPERION's requirements
     provided that such third party shall have executed an appropriate
     confidentiality and non-use agreement; or,
(h)  is required to be disclosed to a regulatory agency of competent
     jurisdiction consistent with the receiving Party's past practice, provided
     that if such agency is not required by law to maintain the confidentiality
     of such information, then the disclosing Party shall first be given the
     opportunity to intervene and contest the disclosure or seek appropriate
     protection.

                                   ARTICLE IX
                            Warranties and Liability

9.01  Success of Development.  OCTOPLUS does not make and shall not be deemed to
      ----------------------
make any representation that OCTOPLUS will successfully and/or timely develop a
Formulation which can commercially be sold.

9.02  Liability.  OCTOPLUS shall be liable solely within the scope of its
      ---------
liability insurance cover of 2.5 Million Dfl, if such insurance does cover the
liability at all, arising from this Development Agreement, except for willful
misconduct.  Any exceeding and further liability - including for patent
infringement - shall be excluded.  In case Clinical Samples or products for
human application will be prepared, except for gross negligence and willful
misconduct caused during performance of the Project by OCTOPLUS, ESPERION shall
be fully liable for all risks connected thereto and shall indemnify and hold
OCTOPLUS harmless accordingly.

                                       12
<PAGE>

9.03  Warranties.  OCTOPLUS warrants that it will use its reasonable best
      ----------
efforts to perform its duties as specified in this Agreement and the agreed
Annexes.  OCTOPLUS does not guarantee that the Development Work, will be
acceptable to any regulatory agency or will be successful in whole or part.
OCTOPLUS will meet the standards of ICH and Regulatory authorities in Europe,
USA and Japan that apply at commencement of each stage of the work.  To the
extent that OCTOPLUS has used its reasonable best efforts hereunder the failure
to meet development requirements or the failure of OCTOPLUS to successfully
perform any analytical or development work shall not constitute a breach by
OCTOPLUS in the performance of its obligations under this Agreement.

                                    ARTICLE X
                              Term and Termination

10.01  Term.  This Agreement shall remain in effect until terminated in
       ----
accordance with Sections 10.03 or 10.04.

10.02  Project On Hold.  ESPERION shall be entitled to put the Development Work
       ---------------
on hold with a notice period of 2 (two) months for a maximum period not
exceeding single or accumulative six months in total. In this event, the Report
delivery period shall be extended accordingly.

10.03  Termination by ESPERION.
       -----------------------

10.03.1. If ESPERION, in good faith, determines that it is not feasible to
jointly develop a Formulation with OCTOPLUS which meets the Specifications, or
that such Formulations cannot be developed in a manner which meets the
milestones, ESPERION shall inform OCTOPLUS of its decision and provide reasons
for same and may, at its option, terminate this Agreement.

10.03.2. ESPERION may terminate this Agreement for any reason other than as set
forth in Section 10.03.1, above, on sixty (60) days notice at any time.

10.04  Termination by OCTOPLUS.  If OCTOPLUS, in good faith, determines that it
       -----------------------
is not feasible to jointly develop a Formulation with ESPERION that meets the
Specifications, OCTOPLUS can terminate this Agreement on sixty (60) days notice.

10.05  Termination for Default.  If either Party shall be in default of any of
       -----------------------
its material obligations under this Agreement, the non-defaulting Party shall
give the defaulting Party written notice of such default, upon which the
defaulting Party shall have forty five (45) days to cure such default or
establish that no default has occurred.  In the event that a default remains
uncured after forty five (45) days have elapsed, the non-defaulting Party

                                       13
<PAGE>

may declare this Agreement terminated, by written notice to the defaulting
Party.

10.06  Surviving Rights.  Neither cancellation or termination of this Agreement
       ----------------
nor the execution of a Manufacturing Agreement, shall relieve the Parties of
their obligations of confidentiality under Article VIII, their obligations as to
inventions under Article VI, or their obligations regarding patent
infringements.

10.07  Effect of Termination.  Should a Party elect to terminate this Agreement
       ---------------------
pursuant to the provisions of this Agreement, neither Party shall thereafter
have any rights to the technology owned by the other Party except if provided
other herein.

                                   ARTICLE XI
                              Patent Infringements.

OCTOPLUS and ESPERION shall each promptly notify the other upon learning of any
infringement of an ESPERION Patent, an OCTOPLUS patent or a jointly owned
patent. Each Party will then cooperate with the other in determining the course
of action to pursue to stop the infringement, with each Party paying its own
expenses involved in any litigation or other actions to stop such infringement.

                                  ARTICLE XII
                            Miscellaneous Provisions

12.01  Reasonable Best Efforts.  The Parties shall both use their reasonable
       -----------------------
best efforts and shall work in good faith and fair dealings to reach agreement
within the Project Group, to achieve the Specifications, complete the Project,
develop Formulations and reach agreement with regard to manufacturing in the
manner described in this Agreement.  Each Party agrees to carry out its assigned
tasks in the Project with reasonable best efforts.

12.02  Manufacturing of Commercial Product.  In case that Project will result in
       -----------------------------------
a product, which can commercially be sold, and if it can be foreseen that
OCTOPLUS will be able to manufacture the commercial product according to
ESPERION's requirements, ESPERION and OCTOPLUS shall then negotiate in good
faith a manufacturing and supply agreement.

12.03  No Guarantee.  The Parties acknowledge that there can be no guarantee
       ------------
that Formulations will within a certain time period be successfully developed
with regard to fitness for a particular use, feasibility of manufacturing,
marketability and all technical, legal and commercial aspects connected thereto.

12.04  Force Majeure.  Neither party shall be responsible or liable to the other
       -------------
party for, nor shall this Agreement be terminated as a result of, any failure

                                       14
<PAGE>

to perform any of its obligations hereunder, if such failure results from
circumstances beyond the control of such party, including, without limitation,
requisition by any government authority, the effect of any statute, ordinance or
governmental order or regulation, wars, strikes, lockouts, riots, epidemic,
disease, an act of God, civil commotion, fire, earthquake, storm, failure of
public utilities, common carriers or supplies, or any other circumstances,
whether or not similar to the above causes and whether or not foreseeable. The
parties shall use their Commercially Reasonable Best Efforts to avoid or remove
any such cause and shall resume performance under this Agreement as soon as
feasible whenever such cause is removed; provided, however, that the foregoing
shall not be construed to require either party to settle any dispute with any
third party, to commence, continue or settle any litigation, or to incur any
unusual or extraordinary expenses.

12.05  No Indirect, Punitive or Exemplary Damages.  Under no circumstances shall
       ------------------------------------------
any Party be liable to the other for damages not specified in this Agreement,
whether direct, indirect, special or consequential, lost profits and/or punitive
damages, provided, that this exclusion of liability does not apply if such
agreement would be invalidated by law (i.e., in the case of intentional
misconduct).

12.06  Settlement of Disputes.  The Project Group shall attempt to amicably
       ----------------------
resolve any dispute concerning any rights or obligations of either Party under
this Agreement.  If the Project Group is unable to resolve any such dispute, the
matter shall be referred to the President of OCTOPLUS and the President of
ESPERION for resolution.

12.07  Choice of Law and Jurisdiction.  This Agreement shall be construed and
       ------------------------------
the rights of the Parties determined in accordance with the laws of The
Netherlands, if ESPERION is the plaintiff and the law of The Netherlands, if
OCTOPLUS is the plaintiff, but regardless of the laws that might otherwise
govern under applicable principles of laws thereof.  In no event shall choice of
law analysis lead to the application of other than Dutch or Swedish law.

The Parties hereto unconditionally and irrevocably agree and consent to personal
jurisdiction and service of process and venue in any court within the city of
The Hague that has jurisdiction, and waive any objection with respect thereto,
for the purpose of any such action, suit or proceeding except in any such court.

12.08  No Jury Trial.  In the event that any dispute or claim of any sort
       -------------
arising out of this Agreement or any subsequent agreement concerning the subject
matter and or any dispute or claim concerning competent court and/or
jurisdiction and/or execution of any award granted by a foreign court or
arbitration panel should be filed, each of the Parties waives irrevocably any
right that such Party may have to demand or request a trial by jury.

                                       15
<PAGE>

12.09  Notices.  Any notice required or permitted to be given under this
       -------
Agreement shall be in writing and shall be deemed to have been sufficiently
given for all purposes if mailed by first class certified or registered mail, or
commercial delivery service, postage prepaid.  Unless otherwise specified in
writing, the mailing addresses of the Parties shall be as described above.

12.10  Titles.  The titles of the Articles and Sections of this Agreement are
       ------
for general information and reference only, and this Agreement shall not be
construed by reference to the titles.

12.11  Severability.  If any provision of this Agreement or the application
       ------------
thereof is adjudicated to be invalid or unenforceable, such invalidity or
unenforceability shall not affect other provisions or applications of this
Agreement which can be given effect without the invalid and unenforceable
provision or application, and to this end, the provisions or applications of
this Agreement shall be severable.  Should any problems in this regard occur or
be threatened, the Parties will inform each other as soon as practical and
renegotiate the relevant provision in good faith but in any event neither Party
shall be obligated to abide by any exclusivity term that is in breach of such
applicable law.

12.12  Amendment.  This Agreement may not be amended, supplemented or otherwise
       ---------
modified except by an instrument in writing signed by both Parties.

12.13  Entire Agreement.  This Agreement, including the Appendices attached
       ----------------
hereto, constitutes and contains the complete, final and exclusive undertaking
and agreement of OCTOPLUS and ESPERION hereto, and cancels and supersedes any
and all prior negotiations, correspondence, understandings and agreements
whether oral or written, between the Parties respecting the subject matter
hereof.

                                       16
<PAGE>

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement by their
respective officer's thereunto duly authorized.

Esperion AB                            Octo Plus b.v.

  /s/ Hans Ageland                       /s/ Dr. Henrik Luessen
------------------------------         ------------------------------------
Name:  Hans Agelan                             Name:  Dr. Henrik Luessen
Title:  CEO                            Title:  Head of Business Development

Date:  05/04/99                        Date:    03/26/99
    --------------------------              -------------------------------

ANNEX A  Project Plan

ANNEX B  Time Period

ANNEX C  Specifications

ANNEX D  ESPERION Data

ANNEX E  Quality Assurance Functions

                                       17
<PAGE>

                                                            OctoPlus BV.
                                                            Niels Bohrweg 11-13,
                                                                  2333 CA Leiden
                                                                 The Netherlands
                                                           Tel. +31(0)71-5680268
                                                           Fax. +31(0)71-5234144
                                                     E-Mail pharmdev@octoplus.nl
                                                        Internet www.octoplus.nl

                          QUALITY ASSURANCE AGREEMENT
         on the development and manufacture of pharmaceutical products
                     between Esperion AB and OctoPlus B.V.
<PAGE>

          Between:  Esperion AB
                    Ekensbergsvagen 115
                    17141 Solna
                    Sweden

               - hereinafter referred to as ESPERION

          and       OctoPlus B.V.
                    Niels Bohrweg 11-13
                    2333 CA Leiden
                    The Netherlands

               - hereinafter referred to as OCTOPLUS

               - an agreement is made as follows:

1.  BASIS OF AGREEMENT

    1.1  This Quality Assurance Agreement is based on the Development Agreement
         (Legal contract) between ESPERION and OCTOPLUS entered into as of . . .
         . . This Agreement Is appended to the Legal contracts between ESPERION
         and OCTOPLUS which covers the commercial and other aspects including
         the costs for special activities and secrecy agreements.

    1.2  OCTOPLUS is a developer manufacturer of pharmaceutical products,
         applying for a manufacturing authorization in accordance with the Dutch
         Drug Law and being subject to monitoring by the competent authorities.
         OCTOPLUS complies with the current recognized ruls such as "RuIes
         governing medicinal products in the European Community", Vol. IV,
         "Guide to Good Manufacturing Practice", for medicinal products
         Including relevant annexes.

    1.3  ESPERION is a developer of pharmaceutical products. ESPERION complies
         with the current recognized rules such as "Rules governing medicinal
         products in the European Community" , Vol. IV, "Guide to Good
         Manufacturing Practice", for medicinal products including relevant
         annexes.

                                       2
<PAGE>

2.  SUBJECT MATTER OF AGREEMENT
    ---------------------------

All alterations of the appendices must be agreed upon by both parties. OCTOPLUS
shall develop and manufacture for ESPERION clinical samples containing Apo-A1
Milano protein for clinical trials.  The overview of functions and
responsibilities is annexed as appendix I.

3.  STARTING MATERIALS
    ------------------

    3.1  Starting materials are defined as:

         3.1.1  Raw materials:

                a. active and inactive Ingredients necessary for the production
                   of the products;

                b. materials that will not remain in the products but which were
                   used for the manufacture of the products (e.g. water, organic
                   solvents);

         3.1.2  Packaging materials.
                All starting materials are listed In appendix II.

    3.2  Purchase

          The responsibility for the purchase of the starting materials is given
          in appendix I.

3.3       Quality control and test records for the starting materials

          3.3.1 OCTOPLUS Is responsible for the quality of the starting
materials purchased by him. These materials shall be analysed with regard to the
specification and methods (defined in the Development Agreement or in the
Pharmacopoeia).

          3.3.2 For the starting materials made available by ESPERION the
quality shall be certified by ESPERION in form of a Certificate of Analysis
which accompanies the shipment of each batch of starting material. The
Specifications and methods are defined in a Development Agreement. OCTOPLUS
shall at least check the following upon receipt of the starting material:

          a.  Intactness of the container and closure

                                       3
<PAGE>

          b.  Congruence of the labeling with the delivery notes

3.4       Storage

          OCTOPLUS stores all starting materials in a way that no interference
          as to their quality may occur.

3.5       Retain samples

OCTOPLUS is responsible for keeping retain samples of each batch of raw
materials purchased by him. These samples shall be kept for at least 2 years
after the end of the trail and after this period they will destroyed after
written authorization by ESPERION.  The size of the samples must be such that it
is possible to perform 2 full quality control analyses (without microbiological
testing).

                                       4
<PAGE>

4.  PRODUCTION
    ----------

    The production of the products shall be performed according to the Current
    Production Formulae and Instructions (appendix III). All alterations of the
    Current Production Formulae and Instructions must be agreed upon by both
    parties in any case. changes can only be done In written consent.

5.  QUALITY CONTROL
    ---------------

    5.1   The Products delivered by OCTOPLUS shall comply with the
          Specifications agreed upon by both parties.

    5.2   For the Judgment of compliance with the specifications the results
          obtained with the test methods listed In appendix IV are relevant.

6.  BATCH RECORDS
    -------------

    6.1  Production and control records

         OCTOPLUS commits himself to keep a record of the production and control
         of each batch for at least 10 years. After this period they will
         destroyed after written authorization by ESPERION. ESPERION has the
         right to view the records during agreed audits.

    6.2  The batch production and control records shall agreed by the partners
         and include at least the following:

                a.  Name and form of product;

                b.  Batch number of product being manufactured;

                c.  Dates and times of commencements of significant intermediate
                    stages and of completion of production

                d.  Batch number or test number and amounts of each starting
                    material used;

                e.  Equipment used including cleaning confirmation

                f.  Any relevant processing operation or event and Its
                    confirmation by signing of the responsible operators;

                g.  Theoretical and actual yields of major steps In the
                    processing detailed information on deviations, exceptional

                                       5
<PAGE>

                    occurrences, e.g. defects and their
                    repairs, signed by and authorized person.

                h.  Results of In-process controls and laboratory testing and
                    decisions following these results;

  6.3  The packaging and labeling records shall agreed by the partners and
       Include at least the following:

                a.  Name and form of product;

                b.  The date(s) and times of the packaging (labeling) operations

                c.  The name of the responsible person carrying out the
                    packaging (labeling) operations

                d.  The Initials of the operators of the different significant
                    steps;

                e.  Records of checks for identity and conformity with the
                    packaging (labeling) instructions including the results of
                    in process controls;

                f.  Details of the packaging (labeling) carried out. Including
                    references to equipment;

                g.  Samples of the printed packaging materials (labeling) used
                    including specimens of the batch coding, expiry dating,
                    study no. If possible and any additional overprinting.

Signature of the responsible production manager and the manager analytical
chemistry;

7.  BATCH ACCOMPANYING DOCUMENTS
    ----------------------------

    OCTOPLUS commits himself to deliver with every batch a certificate of
    compliance (appendix V) according to the a.m. Specifications.

8.  RETAIN SAMPLES OF THE PRODUCTS
    ------------------------------

    OCTOPLUS Is responsible for keeping retain samples of each batch of product
    of this agreement. These samples shall be kept for at least 2 years after
    the end of the trial and after this period they will destroyed after written
    authorization by ESPERION. The size of the samples must be such that it is
    possible to perform 2 full quality control analyses (without microbiological
    testing).

                                       6
<PAGE>

9.  RELEASE
    -------

    The release of the Products for shipment is In the responsibility of
    OCTOPLUS. Final release of the product is in the responsibility of OCTOPLUS.
    ESPERION reserves the right to reject batches in case of noncompliance with
    this agreement. However, the parties shall attempt in good faith to settle
    the controversies and to agree in writing on the action to be taken.

10.  STORAGE, PACKAGING, SHIPMENTS
     -----------------------------

     Storage conditions and packaging instructions for the shipment of the
     products are laid down In appendix VII of this agreement

11.  THIRD PARTIES
     -------------

     OCTOPLUS may employ third parties with the execution of the tasks given to
     him by ESPERION.  These third parties and their duties have to be listed In
     the Overview of Functions and Responsibilities indicating the name of the
     third party (appendix I). The responsibility regarding the quality of the
     Product and all legal requirements therewith connected rests with OCTOPLUS
     and cannot be transferred to a third party. Any change with regards to this
     matter Is subject to a mutual agreement between ESPERION and OCTOPLUS and
     is required to be approved by both parties in a written form.

                                       7
<PAGE>

12.  AUDITS
     ------

     OCTOPLUS agrees that ESPERION have the right to audit the premises where
     the products are manufactured, including packaging, storage, quality
     control and distribution.  -
     These audits will be scheduled to be mutually convenient to both parties
     referable when the product is produced. Mutually agreed corrective actions
     resulting from the observations during the Inspection have to be performed
     in the soonest possible way. OCTOPLUS will report to ESPERION about his
     efforts in the carrying out of the corrective actions within a laid down
     time frame. ESPERION shall announce such audit within a reasonable time but
     at least one-month in advance to OCTOPLUS.

13.  QUALITY DEFECTS
     ---------------

     Both parties agree to contact each other immediately as soon as they become
     aware of quality defects. The quality defects and the communication should
     be well documented.

14.  RETURNS
     -------

     Products should be returned to OCTOPLUS instructions for the shipment of
     the products are laid down in appendix VII of this agreement. These
     products shall be kept for at least 2 years after the end of the trail and
     after this period they will destroyed after written authorization by
     ESPERION.

15.  PERSONS TO CONTACT
     ------------------

     The relevant persons which should be contacted in case of questions that
     may arise concerning all pharmaceutical/technical matters which are objects
     of this agreement are listed in appendix II.

16.  CONFIDENTIALITY
     ---------------

     OCTOPLUS and ESPERION undertake to apply strict confidentiality with regard
     to their know how and in particular their manufacturing Instructions. None
     of the contracting parties shall be entitled to use the know how of the
     other party made known within the framework of this agreement after
     termination of this agreement without the consent of the other party.

                                       8
<PAGE>

17.  FINAL PROVSIONS
     ---------------
          a.  This agreement shall become effective upon its signature by the
              parties

          b.  Any alteration or amendments of this agreements and its appendices
              requires the written consent of both parties.

          c.  Supplementary agreements are listed - if necessary - in appendix
VII.

          d.  Upon request parts of this agreement may be forwarded to the
              competent authorities.

          e.  If individual provisions of this agreement are invalid, they shall
              be replaced by provisions which come as dose to the intended
              provisions as is admissible.

Signatures:

ESPERION                        OCTOPLUS B.V.

Stockholm    June 7, 1999       Leiden,  16 June 1999
-------------------------       -------------------------------
(place, date)

/s/ Hans Ageland                 /s/
-------------------------       -------------------------------
(responsible person)

-------------------------       -------------------------------
(responsible person)

-------------------------       -------------------------------
(responsible person)

                                       9<PAGE>

                                                                   EXHIBIT 10.21

                             Production Agreement

                                   Project:

This Production Agreement (hereinafter the "Agreement") is entered into the 7th
day of March, 2000

by and between

ESPERION THERAPEUTICS, INC., a Delaware corporation located at 3621 S. State
Street, 695 KMS Place, Ann Arbor, Michigan 48108, USA, hereinafter referred to
as "ESPERION",

and

EUROGENTEC S.A., a Belgian corporation located at Parc Scientifique du Sart
Tilman, B-4102 Seraing, Belgium, hereinafter referred to as "EUROGENTEC",
hereinafter referred to individually as "a Party" or collectively as "the
Parties",

Whereas the Parties wish to set forth in writing the terms and conditions under
which EUROGENTEC will produce and supply to ESPERION, and ESPERION will purchase
from EUROGENTEC, batches intended to be used in research, research
(phamacokinetics, toxicology, stability, scale-up processes, production
consistency, etc.), clinical development, scaling up of process, and production
of consistency of ESPERION's compound Pro-Apolipoprotein A-I, in EUROGENTEC's
production facilities at Seraing.  The number of weeks required for of usage of
EUROGENTEC's production facility is defined in Annex 3.

Now it is hereby agreed as follows:

Article 1  : Definitions

1.1  "Cell Bank" shall mean Master Cell Bank or derived Cell Bank including GMP,
GLP and Working Cell Banks.

1.2  "Current Pharmaceutical Guidelines" shall refer to guidelines described in
US 21 Part.  210 and 211 CFR cGMP regulation, US 21 Part.  600 CFR (additional
regulation for Biologicals) and EC Guide to Good Manufacturing Practices.

1.3  "Clinical Batch" shall mean the fermentation of a strain of Escherichia
coli (hereafter referred to as the "Strain") expressing the compound Pro-
Apolipoprotein Al (hereinafter referred to as the "Product") and the
purification of the Product in EUROGENTEC's pharmaceutical Production Unit, as
hereinafter defined, applying Current Pharmaceutical Guidelines, with the
intention to use the Product for research, preclinical research
(phamacokinetics, toxicology, stability, scale-up processes, production
consistency, etc.), and clinical development.

1.4  GMP shall mean the current rules for "Good Manufacturing Practice" as
defined and published by the US Food and Drug Administration and the European
Union equivalent administration for the manufacture of pharmaceutical products.
<PAGE>

1.5  "Product" shall mean human recombinant proapoplipoprotein A-I.

1.6  "Specification documents" shall mean the preparation and production
instructions for each Clinical Batch, including batch protocols and records,
identification of raw materials and specific instrumentation, the specifications
for the Product, the identification of critical steps, the quality control
methods and all information necessary to carry out the production and quality
control operations.

Article 2  : The Production of Clinical Batches

2.1  EUROGENTEC shall diligently manufacture in its Production Unit Clinical
Batches of the Product as ordered by ESPERION in accordance with the Current
Pharmaceutical Guidelines and Specification documents (as defined in Annex 1) to
be supplied by ESPERION before each Clinical Batch production.

2.2  The general responsibilities of EUROGENTEC and ESPERION for the preparation
of Clinical Batches and/or Cell Banks are defined in Annex 1, which forms an
integral part of this Agreement.

2.3  The products resulting from Clinical Batches produced by EUROGENTEC are
bulk proapolipoprotein A-I for injection to be used in research, preclinical
research (phamacokinetics, toxicology, stability, scale-up processes, production
consistency, etc.), and clinical development to be conducted on a world-wide
basis under the responsibility of ESPERION.

2.4  The production planning of Clinical Batches will be jointly defined by the
Parties.  The Specification documents will be made available to EUROGENTEC by
ESPERION in due time to allow EUROGENTEC to produce in accordance with the
Current Pharmaceutical Guidelines.

2.5  EUROGENTEC shall diligently assure the consistency of manufactured batches.

Article 3  : EUROGENTEC Production Unit, Equipment & Personnel

3.1  The preparation of Clinical Batches or Cell Banks will take place in the
pharmaceutical multipurpose production unit of EUROGENTEC located at Parc
Scientifique du Sart Tilman, B- 4102 Seraing, Belgium (phone 32.4.366.01.50 &
fax 32.4.365.16.04) (the "Production Unit").  The Production Unit will be
maintained, cleaned and operated by EUROGENTEC in compliance with Current
Pharmaceutical Guidelines.

3.2  A currently registered (in Belgium) pharmacist, with knowledge of cGMP
requirements, on EUROGENTEC's payroll will control the production of Clinical
Batches.

3.3  ESPERION reserves the right to use some areas of the Production Unit (as
such use is defined in Annex 3) for the period defined in Annex 3.

                                       2
<PAGE>

Article 4  :Auditing

4.1  ESPERION, or a party designated by ESPERION, shall be permitted to audit
the Production Unit of EUROGENTEC from time to time upon reasonable prior notice
to EUROGENTEC.

4.2  The responsibilities for Quality Control sampling will be defined in the
Process Document (as defined in Annexes 1 and 2 attached hereto).  Samples from
each Clinical Batch shall be kept at EUROGENTEC and shall be transferred to a
location designated by ESPERION within two weeks upon the later of(a) one (1)
year after the concerned Clinical Batch expiry date, or (b) two (2) years after
the end of clinical studies upon ESPERION's request.

Article 5  :Compliance with Legal Requirements

5.1  All activities to be performed by EUROGENTEC under this Agreement and in
the Production Unit shall comply with requirements enacted by the Belgian
Ministry of Health, the U.S.  Food and Drug Administration and any other
relevant authority and shall be in compliance with Current Pharmaceuticals
Guidelines and all applicable legal requirements.  EUROGENTEC shall obtain and
maintain any required authorization for the performance of this Agreement.

5.2  In particular, EUROGENTEC warrants to ESPERION that the Production Area
dedicated to the performance of this Agreement as defined in Annex 3 will be
independent from any other activity and that all precautions shall be taken by
EUROGENTEC in order to avoid any cross contamination.

5.3  EUROGENTEC and ESPERION shall cooperate and be diligent in responding to
all requests for information from, and in making all required filings with,
regulatory authorities having jurisdiction to make such requests or require such
filings.  EUROGENTEC shall obtain and comply with all current licenses,
consents, permits and regulations which may from time to time be required by
appropriate legal and regulatory authorities with respect the performance of its
obligations hereunder.

Article 6  :Price and Payment Conditions

6.1  All prices hereunder are in BEF and are exclusive of VAT.  The prices to be
paid by ESPERION for the performance of this Agreement are set forth in Annex 4
attached hereto, which forms an integral part of this Agreement.  The total cost
for technology transfer is defined in Annex 4.   The total cost for production
is defined in Annex 4.

6.2  The exchange rate for conversion of BEF to US dollars shall be equal to a
rolling three (3) month average exchange rate, calculated during the period
covered by the services provided and starting with the month in which services
commenced..

6.3  Raw materials, including entry QC and specific consumables, needed for the
production of Clinical Batches or Cell Banks under this Agreement, other than
chemical materials used by EUROGENTEC in quality control activities, are not
included in the price referred to in Article

                                       3
<PAGE>

6.1. and will be supplied and invoiced separately by EUROGENTEC. The total costs
for raw materials is defined in Annex 4.

6.4  ESPERION shall pay upon signature of this Agreement an advance payment of
30% of the estimated price defined in Annex 4 attached hereto.  This advance
payment shall be deducted proportionally from each invoice due to EUROGENTEC
under Article 6.1.  In the event that ESPERION terminates or cancels this
Agreement for any reason whatsoever, except for negligence, misconduct or
default of EUROGENTEC, Esperion shall pay only for costs incurred as of the time
of termination.  All materials produced as of the time of termination shall be
returned to ESPERION or destroyed at ESPERION's discretion.

6.5  EUROGENTEC shall send monthly invoices to ESPERION together with supporting
documentation, and payment will be made by ESPERION within thirty (30) days from
date of receipt of such invoice.

Article 7  : Liabilities of EUROGENTEC

7.1  EUROGENTEC warrants that the Clinical Batches manufactured and supplied
hereunder to ESPERION shall be manufactured in accordance with Current
Pharmaceutical Guidelines and shall conform to the Specification documents.  The
foregoing is the exclusive warranty of ESPERION for defects in the Clinical
Batches manufactured by EUROGENTEC under this Agreement and is in lieu of any
other warranty, express or implied, including but not limited to, implied
warranty of merchantability or fitness for a particular purpose.  EUROGENTEC
shall have no liability hereunder for incidental or consequential damages,
including lost profits.

7.2  ESPERION shall have the right to give EUROGENTEC written notice of
rejection of any shipment of Clinical Batch that in whole or in part breaches
EUROGENTEC's warranties, covenants and obligations under this Agreement, which
notice shall be given within thirty (30) days after discovery of such breach
however not later than 90 days after receipt of shipment.  If there is
disagreement between the parties as to whether the Clinical Batch meets
Specification documents, the parties shall have such Clinical Batch tested by a
mutually agreed upon third party and such party's determination as to whether
such Clinical Batch meets Specification documents shall be binding on the
parties hereto.  The expense for such testing and for any costs associated with
the destruction of such Clinical Batch shall be borne by EUROGENTEC except to
the extent it is determined that EUROGENTEC is not responsible for such failure
or breach.  At ESPERION's option, EUROGENTEC shall promptly replace any Clinical
Batch which does not conform with EUROGENTEC's warranties under this Agreement.
ESPERION shall have the right to setoff any refund due ESPERION on account of
any rejected Clinical Batch against invoices otherwise due or which become due
to EUROGENTEC.  The provisions of this Article 7.2 shall survive termination of
this Agreement.

7.3  EUROGENTEC shall indemnify, defend and hold ESPERION, each affiliate of
ESPERION and the officers, directors, stockholders and employees thereof (each
an "ESPERION indemnified party") harmless from and against any and all losses,
liabilities, damages, claims, expenses, suits, recoveries, judgments and fines
(including reasonable attorneys' fees and expenses) (collectively "Losses") that
may be incurred by any ESPERION

                                       4
<PAGE>

indemnified party or any third party arising out of any (a) actual or alleged
damage to property or injury or death occurring to any person arising out of
possession, use or consumption by any person of the Clinical Batches to the
extent that such damage, injury or death was caused by the failure of such
Clinical Batches to meet Specification documents; (b) claim, action or
proceeding brought by any governmental or regulatory authority arising out of or
resulting from any breach of EUROGENTEC under this Agreement; or (c) breach by
EUROGENTEC of any of its obligations, representations or warranties under this
Agreement.

7.4  If the first 300 grams of Product is not delivered by EUROGENTEC in
accordance with the time schedule set forth in Annex 3, EUROGENTEC shall pay to
ESPERION, as liquidated damages for such delay and not as a penalty, an amount
equal to 5% of the aggregate price hereunder for such undelivered quantity for
each week (or part thereof) of delay beyond the scheduled delivery date up to a
maximum of US$350,000.  If any quantity of Product after of such first 300
grams is not delivered by EUROGENTEC in accordance with the time schedule set
forth in Annex 3, EUROGENTEC shall pay to ESPERION, as liquidated damages for
such delay and not as a penalty, an amount equal to 10% of the aggregate price
hereunder for such undelivered quantity for each week (or part thereof) of delay
beyond the scheduled delivery date.  Such liquidated damages shall be payable by
EUROGENTEC to ESPERION on demand or, at the option of ESPERION, may be offset by
ESPERION against any amount owed by ESPERION to EUROGENTEC under this Agreement.
Such liquidated damages cover only damages resulting from such delay in delivery
and shall not limit or affect any other claims or rights which ESPERION may have
hereunder or under applicable law.  For delivery of future batches, EUROGENTEC
shall pay to ESPERION the liquidated damages for delay and not as a penalty, an
amount equal to 5% of the aggregate price hereunder for such undelivered
quantity for each week (or part thereof) of delay beyond the scheduled delivery
date up to a maximum of 35% of the aggregated price not to exceed US$1,000,000.

7.5  EUROGENTEC shall have no liability hereunder for incidental or
consequential damages, including lost profits.

Article 8  : Liability of ESPERION

8.1  ESPERION warrants to EUROGENTEC that the use of the Strain will not involve
a risk for the human beings, the animals and the environment that would require
more than a containment level 2 as defined in directive 98/81/EC.  In case of
recombinant microorganisms, ESPERION and EUROGENTEC shall agree upon an
appropriately validated procedure for the inactivation of the Strain.

8.2  ESPERION shall indemnify and hold EUROGENTEC harmless from and against any
and all Losses asserted by any third party arising out of or in connection with
the use of the Strain by EUROGENTEC or its employees if the Strain supplied by
ESPERION does not conform to the specifications described in this Agreement and
its Annexes, in particular in Article 8.1., or with the use of any products
derived from the Clinical Batches delivered by EUROGENTEC to ESPERION in
accordance with this Agreement, except if such damages were caused by
negligence, misconduct or breach of this Agreement on the part of EUROGENTEC or
its employees, subject to the terms and conditions provided for in Article 7.

                                       5
<PAGE>

8.3  ESPERION shall have no liability hereunder for incidental or consequential
damages, including lost profits.

Article 9  : Intellectual Property Rights

9.1  ESPERION agrees to indemnify and hold EUROGENTEC harmless from and against
any and all claims, demands, causes of action, actions or suits, arising out or
related to any intellectual property rights whatsoever owned by any third
parties on techniques, know-how or materials used by EUROGENTEC in the
performance of EUROGENTEC activities covered by this Agreement, which either are
supplied by ESPERION or are acquired by EUROGENTEC on behalf of ESPERION at
ESPERION's request.

9.2  ESPERION shall grant to EUROGENTEC a non-exclusive license for use of its
necessary proprietary technologies, know-how and materials for the sole purpose
of EUROGENTEC' s performance under this Agreement.  EUROGENTEC warrants that any
of its employees having access to such ESPERION's proprietary technologies,
know-how and materials : (i) shall be made aware of the confidentiality of such
technologies, know-how and materials; (ii) shall be bound by confidentiality
agreements in place; (iii) will keep such technologies, know-how and materials
in strict confidence; and (iv) will not disclose same to any third party.

9.3  Any proprietary technologies, information, know-how and materials owned by
ESPERION or provided by ESPERION to EUROGENTEC in connection with this Agreement
shall not be used by EUROGENTEC in the manufacture of any products or batches
(other than the Clinical Batches manufactured for ESPERION) or disclosed or made
available to any customers of EUROGENTEC or other third parties.  All such
information shall be deemed confidential information subject to the provisions
of Article 10.

9.4  EUROGENTEC shall not enter into any agreement to manufacture any product
with the same properties as Proapolipoprotein A-I.

9.5  (a)  If any improvements or modifications to the Product are developed by
ESPERION or EUROGENTEC, either jointly or severally, such improvements or
modifications shall be the exclusive property of ESPERION and shall be held in
confidence by EUROGENTEC for ESPERION's sole benefit in the development and/or
the operation of manufacturing processes with respect to the Product.
EUROGENTEC shall disclose to ESPERION and receive the approval of ESPERION with
respect to all such improvements or modifications relating to the manufacturing,
and/or packaging process of the Products or use of the Products developed by
EUROGENTEC.  Any trademarks, trade names, brand names, patents, slogans, logos,
copyrights, trade dress, know-how and goodwill associated with the Product shall
be the sole and exclusive property of ESPERION.  EUROGENTEC shall have no right
or license to use any such rights at any time before, during or after the term
of this Agreement, except as necessary for the manufacture, processing,
packaging and supply of Clinical Batches to ESPERION hereunder.

                                       6
<PAGE>

     (b)  It is agreed that ESPERION is the sole owner of any and all
Specification documents supplied or paid for by ESPERION, and EUROGENTEC shall
not use any such Specification documents except in connection with its
performance under this Agreement.

     (c)  The provisions of this Article 9.4 shall survive the termination or
expiration of this Agreement.

Article 10  : Confidentiality

10.1  Inasmuch as some of the information and data intended to be exchanged
between the parties may be confidential and proprietary to a party hereto, each
of the parties hereto agrees with the other that the party receiving the
confidential information (hereinafter the "Recipient Party") will maintain as
secret and confidential and will not disclose to third parties without written
permission from the Party disclosing the information (hereinafter the
"Disclosing Party") any trade secrets and other confidential information gained
from discussions, or in any other way, including but not limited to, formulae,
descriptions, specifications and the like disclosed by or obtained from the
Disclosing Party.  The provisions contained in this Article 10.1 shall survive
the termination or expiration of this Agreement.

10.2  The Recipient Party and its representatives will not practice any of the
trade secrets and other confidential information of the Disclosing Party without
first obtaining a license from the Disclosing Party to do so.

10.3  For purposes of this Agreement, the term "trade secrets and other
confidential information" shall include and be limited to, information disclosed
by the Disclosing Party to the Recipient Party that: (i) was not known to the
Recipient Party at the time of such disclosure; (ii) at the time of disclosure
was not or did not later on become known to or available to the public; or (iii)
was not disclosed to the Recipient Party by any other Party legally entitled to
disclose such information who did not, in turn, require the Recipient Party to
keep the information confidential.

Article 11  : Duration and Termination

11.1  This Agreement shall become effective as of March 7, 2000 and shall remain
in full force and effect until the delivery of all of the Clinical Batches or
                                                                           --
for a period of 5 years, unless extended or renewed by mutual agreement in
writing.

11.2  Either party may forthwith terminate this Agreement by giving a written
notice to the other if the other party commits any material breach of this
Agreement and, if the breach is capable of remedy, fails to remedy it within 30
days of receipt of a written notice specifying such breach.

11.3  ESPERION may terminate this Agreement at any time upon 30 days prior
written notice to EUROGENTEC.

11.4  The provisions of articles 7, 8, 9 and 10 shall continue in force in
accordance with their terms, notwithstanding expiry or termination of this
Agreement for any reason.

                                       7
<PAGE>

Article 12  : GMP Requirements

12.1  Documents to be submitted by both parties before and after a Clinical
Batch production and approval procedures of such documents are detailed in Annex
1 attached hereto.

12.2  EUROGENTEC shall issue to ESPERION monthly written reports detailing its
activities for each Clinical Batch.

12.3  EUROGENTEC agrees to have the production facility and records for Product
inspected and/or audited by relevant regulatory agencies of any country and
shall provide a copy of requested documents to authorities.

12.4  EUROGENTEC shall provide for technology transfer to any institutions upon
the request of ESPERION and at ESPERION's expense based on a daily rate.

Article 13  : Miscellaneous

13.1  If any party hereto is delayed or prohibited from fulfilling its
obligation or obligations under this Agreement for any reason beyond its
reasonable control, including without limitation, reason of fire, war,
embargoes, acts of God, unavailability of raw materials, breakdown of or damage
to machinery, or equipment, strike, lock out or other labor dispute, any rule,
order or regulation of any governmental authority, domestic or foreign, or any
other cause or occurrence beyond the reasonable control of such party, and, if
prompt written notice of said delay or prohibition shall be given to the other
party, then performance of said obligation or obligations shall be excused for
the period of time during which the cause of such delay or prohibition shall
continue, provided that the party so impeded shall have made reasonable efforts
to minimize any such delay.

13.2  All notices which are required to be given under this Agreement shall be
deemed to have been sufficiently given if in writing and sent by registered mail
or express courier with the requisite postage affixed, or if by fax, confirmed
by registered mail or expressed courier addressed to the party notified, at the
address set forth in the preamble above, or such other address as may
hereinafter be given by such party to the other for notice purpose.  The date of
such delivery, or five (5) days after the date of such mailing, shall be the
date of service of such notice.

13.3  This Agreement, together with all annexes thereto which form an integral
part thereof, supersedes any previous agreements and understandings and
constitutes the entire agreement between the parties hereto relating to the
subject matter hereof.  Any amendments, modifications, variations, or waivers,
including amendments and modifications to the various annexes must be in writing
and signed by both parties hereto.

13.4  This Agreement shall not be construed to make either party a legal
representative of the other party or to give either party any right or power to
bind the other party to any contract or the performance of any obligation to or
with any third party.

                                       8
<PAGE>

13.5  Each party shall conduct its operations as an independent contractor and
no claims for taxes of any kind, nor claims arising out of labor laws, nor any
other claims asserted against one party may be asserted against the other as a
consequence of this Agreement.

13.6  (a)  Any dispute, controversy or claim arising out of, relating to, or in
connection with, this Agreement, or the breach, termination or validity thereof,
shall be governed by and construed in accordance with the laws of the State of
New York, without reference to choice of law doctrine, and shall be finally
settled by arbitration.

      (b)  The arbitration shall be conducted in accordance with the World
Intellectual Property Organization Arbitration Rules in effect at the time of
the arbitration (the "WIPO Rules"), except as they may be modified herein or by
mutual agreement of the parties.

     (c)   The seat of the arbitration shall be in Geneva, Switzerland, and the
arbitration shall be conducted in the English language, provided, however, that
either party may submit testimony or documentary evidence in French but shall,
on the request of the other party, furnish a translation or interpretation into
English of any such testimony or documentary evidence.

     (d)   The arbitral tribunal shall consist of a sole arbitrator who shall be
selected as provided for in the WIPO Rules, except that such arbitrator must be
free of any potential for bias or conflict of interest with respect to any of
the parties to the dispute, whether directly or indirectly; be in a position to
hear the dispute immediately and thereafter render a decision within the time
specified, and be a party who is familiar with the biotechnology field.

     (e)   At the request of a party, the arbitrator may take such interim
measures as he deems necessary in respect of the subject matter of the dispute.
In addition to the authority conferred on the arbitrator by the WIPO Rules
specified above, the arbitrator shall have the authority to order reasonable
discovery and production of documents.

     (f)   The arbitral award shall be in writing, decided in accordance with
law, state the reasons for the award, and be final and binding on the parties.
The award may include an award of costs, including reasonable attorneys' fees
and disbursements. Judgment upon the award may be entered by any court having
jurisdiction thereof or having jurisdiction over the parties or their assets.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed
by their duly authorized officers on the date first above written.

<TABLE>
<S>                                          <C>
EUROGENTEC S.A.                              ESPERION THERAPEUTICS, INC.

By: /s/ Dr. Michel Thiry                     By: /s/ Dr. Roger Newton
    ------------------------------               ---------------------------------------------
    Dr. Michel Thiry                             Dr. Roger Newton
    Biopharmaceutical B.U. Manager               Esperion Therpeutics Inc., President and CEO

By: /s/ Jean Pierre Delwart                  By:
    ------------------------------               ---------------------------------------------
    Jean Pierre Delwart
    Administrateur-Delegue
</TABLE>

                                       9
<PAGE>

                                    Annex 1

               Production of Clinical Batch and Master Cell Bank

ARTICLE 1  : Definitions

1.1  "Product" shall mean the properly packed amount of bulk of human
     proapolipoprotein A-I resulting from the Clinical Batch or, in case of
     master cell banks, the properly packed amount of viable Strain with its
     buffer, bottle caps and labels.

1.2  The "Specification Document" shall include the manufacturing instructions,
     including the identification of raw materials ("Bill of Material") and
     specific instrumentation, the specifications for the Product (including in
     case of master cell bank preparations, type and number of vials), the
     identification of critical steps and the QC methodologies ("Product Control
     Specification").

1.3  The "Process Document" shall include the procedures established by
     EUROGENTEC to adapt the manufacturing and QC operations defined in the
     Specification Document to a pharmaceutical production into its facilities
     applying the Current Pharmaceutical Guidelines. It shall also include
     general requirement under the Current Pharmaceutical Guidelines related to
     the use of EUROGENTEC' personnel, equipment and Production Unit, and to the
     preparation of documentation pertaining to the Clinical Batch operations.

1.4  The "Manufacturing Batch Record" is the collection of all manufacturing and
     control documentation regarding each single batch of the Product.

1.5  All other capitalized terms not defined in this Annex I shall have the
     meaning as described to such terms in the Production Agreement of which
     this Annex 1 forms an integral part.

ARTICLE 2  General responsibilities of ESPERION

2.1  For each Clinical Batch it orders and in due time before the starting of
     the production, ESPERION will provide EUROGENTEC with the Specification
     Document necessary to carry out the manufacturing and QC operations.

2.2  ESPERION will provide EUROGENTEC with the initial Strain as a glycerol
     suspension to be stored at - 70(degrees)C with the GMP certificate joined.
     Shipment of the Strain is under ESPERION's responsibility. Identity of the
     Strain after shipment is under ESPERION's responsibility, provided
     EUROGENTEC properly stores the Strain at - 70(degrees).

2.3  ESPERION will promptly communicate to EUROGENTEC any change related to the
     Specification Document.

2.4  ESPERION will promptly approve the Process Document prepared by EUROGENTEC
     before implementation of the production by EUROGENTEC. EUROGENTEC shall
     ensure that the manufacture of Pro-Apolipoprotein A-I shall take place in
     strict
<PAGE>

     accordance with the Process Document (defined after discussion with
     EUROGENTEC and after feasibility study).

2.5  EUROGENTEC does not warrant that modifications to the Specification
     Document introduced by ESPERION after approval of the Process Document by
     ESPERION will be included in the manufacturing process.

2.6  EUROGENTEC will be responsible for batch numbering of the Product.

ARTICLE 3  : General responsibilities of EUROGENTEC

3.1  EUROGENTEC commits to accomplish its contracting work according to the
     Current Pharmaceutical Guidelines.

3.2  EUROGENTEC will be responsible for carrying out validation and control in
     the following areas:

     .  HVAC and room classification,
     .  Purification water system,
     .  Calibration of EUROGENTEC equipment,
     .  Sterilisation and decontamination equipment,
     .  Cleaning procedures.

3.3  EUROGENTEC will perform environment monitoring (Air, Surfaces) and water
     testing.

3.4  EUROGENTEC will prepare the Process Document and will request ESPERION's
     approval thereon before implementation.

3.5  EUROGENTEC will make no changes to the Process Document without formal
     approval of ESPERION. However, changes referring to the document lay-out or
     internal procedures are not subject to formal ESPERION's approval.

3.6  EUROGENTEC will prepare the Manufacturing Batch Record. The original
     Manufacturing Batch Record will be kept at EUROGENTEC and will be archived
     for a period of 2 years after the clinical trials. A copy will be delivered
     to ESPERION with the Product ESPERION.

3.7  EUROGENTEC will not subcontract any work without the prior written consent
     of ESPERION.

ARTICLE 4  Raw material

4.1  All raw materials will be QC controlled wider the responsibility of
     EUROGENTEC and released by EUROGENTEC in due time before production of each
     Clinical Batch.

ARTICLE 5  : Manufacturing

                                                                               2
<PAGE>

5.1  Division of responsibilities between the parties concerning the
     manufacturing operations is specified in Annex 2 which is considered to be
     part of the Agreement.

5.2  Modification to the Process Document may be required if a conflict between
     a specific process contained in the Process Document and the spirit of the
     Current Pharmaceutical Guidelines is observed during the manufacturing
     operations. Such modification will be subject to approval by ESPERION
     before EUROGENTEC can continue the manufacturing process. ESPERION's
     failure to approve or reject the modification in due time will free the
     responsibility of EUROGENTEC concerning the failure to manufacture the
     Product.

ARTICLE 6  Release of Product

6.1  The Qualified Person of EUROGENTEC will review each single Manufacturing
     Batch Record for compliance with the Process Document. EUROGENTEC will
     release each single batch for shipment to ESPERION only after full
     compliance of the batch documentation with the Process Document. He will
     notify ESPERION of any significant deviation prior to release and shipment.

6.2  The Qualified Person of EUROGENTEC will notify the release of each single
     batch to ESPERION by means of a product specific release certificate
     limited to the manufacturing specifications and the specifications of the
     controls being performed by EUROGENTEC or by an external contractor under
     its responsibility.

6.3  An appropriate number of samples of Product or amount of intermediate
     active ingredient, as specified in the Specification Document, will be
     conserved by EUROGENTEC for retesting in case of disagreement between
     EUROGENTEC and ESPERION about EUROGENTEC' responsibility in Product failure
     to conform to the product specifications.

ARTICLE 7  Storage and transport

7.1  The transport of the Product will be organized by ESPERION and will be done
     under its own responsibility and at its own expenses.

7.2  If physically possible, EUROGENTEC may store the Product for a short period
     of time upon ESPERION's prior agreement.

                                                                               3
<PAGE>

                                    Annex 2

              Clinical Batch:  Responsibilities for Manufacturing

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
                                                                                       Responsibilities
           Area                           Activity or event                        -----------------------              Comment
                                                                                   EUROGENTEC  Contracting
                                                                                                 Partner
------------------------------------------------------------------------------------------------------------------------------------
<S>                          <C>                                                   <C>         <C>                      <C>
Initiate                     Obtain batch order                                                    X

                             Inspect and release facilities and equipment for use      X
------------------------------------------------------------------------------------------------------------------------------------
Raw Materials
                             Purchase of raw materials                                 X
                             Release of raw materials                                  X
Manufacture                  Manufacture                                               X
Fermentation, downstream &   Establishing sample procedures                            X
harvesting                   Perform sampling                                          X               -----------------------------
                             Perform in-process testing                                X
                             Perform release testing on intermediaries
                             Decide rework on intermediates                            X                      If acceptable
                                                                                                             according to GMP
------------------------------------------------------------------------------------------------------------------------------------
Manufacture                  Manufacture                                               X
(purification)               Establish sampling procedures                                         X
                             Perform Sampling                                          X
                             Perform in-process testing (IPC)                          X
                             Perform release testing on intermediates                  X

                             Decide work on intermediates                              X                      If acceptable
                                                                                                             according to GMP
------------------------------------------------------------------------------------------------------------------------------------
Quality assurance            Perform environmental testing                             X               Copies of all records shall
                             Maintain test records                                     X               be provided to Esperion
                             File batch record                                         X
                             Audit bulk operations                                     X           X
-------------------------------------------------------------------------------
Release/Reject/Rework        Review and release batch record                           X       ------------------------------------
                             Release/reject batch                                      X               Contacting Partner may
                                                                                                       reject a batch released by
                                                                                                       EUROGENTEC
                             Resolved and document any manufacturing problems          X
                             not implying rework

                             Dispose of rejected material                                          X
                             Maintain reject records                                   X
</TABLE>

                                       4
<PAGE>

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
                                                                                      Responsibilities
           Area                   Activity or event                                -----------------------              Comment
                                                                                   EUROGENTEC  Contracting
                                                                                                Partner
----------------------------------------------------------------------------------------------------------------------------------
<S>                          <C>                                                   <C>         <C>                      <C>
                             Store release bulk                                        X
                             Reconcile material usage                                  X
QC                           Take and store retention samples                          X
                             Take and store stability samples                                          X
                             Operate bioburden program for facilities and              X
                             equipment
                             Perform release testing on purified bulk                  X               X
                             Provide process analytical guide                                          X
-----------------------------------------------------------------------------------------------------------------------------------
Cleaning                     Dispose of unused materials                               X
                             Clean facilities and equipment                            X
                             Establish and update cleaning procedures                  X
-----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                       5
<PAGE>

                                    Annex 3

                                  The Project

ARTICLE 1  : Definitions

(A listing of the various steps required to achieve the project)

ARTICLE 2  : Schedule

(A precise table of succession of the various steps and their duration)

ARTICLE 3  : Resources implications

-------------------------------------------------------------------------------
           ACTIVITIES              % of implication for the       DURATION
                                          project
-------------------------------------------------------------------------------
FERMENTATION Production Team
-------------------------------------------------------------------------------
DOWN-STREAM Production Team
-------------------------------------------------------------------------------
FERMENTATION Development Team
-------------------------------------------------------------------------------
DOWN-STREAM Development Team
-------------------------------------------------------------------------------
QC Team
-------------------------------------------------------------------------------
AQ Team
-------------------------------------------------------------------------------
Management, maintenance &
 logistics
-------------------------------------------------------------------------------
<PAGE>

                                    Annex 4

                                   The Price

ARTICLE 1 : Definitions

     All prices are in BEF and are exclusive of VAT.

ARTICLE 2  Article 2 : Price list

------------------------------------------------------------------------------
          ACTIVITIES                    PRICE PER WEEK (MONTH)
------------------------------------------------------------------------------
FERMENTATION Production Team
------------------------------------------------------------------------------
DOWN-STREAM Production Team
------------------------------------------------------------------------------
FERMENTATION Development Team
------------------------------------------------------------------------------
DOWN-STREAM Development Team
------------------------------------------------------------------------------
QC Team
------------------------------------------------------------------------------
AQ Team
------------------------------------------------------------------------------
Management, maintenance & Logistics
------------------------------------------------------------------------------

ARTICLE 3 : Price estimation for the Project

           ACTIVITIES              % of implication for    DURATION     PRICE
                                        the project                   ESTIMATION
--------------------------------------------------------------------------------
FERMENTATION Production Team
--------------------------------------------------------------------------------
DOWN-STREAM Production Team
--------------------------------------------------------------------------------
FERMENTATION Development Team
--------------------------------------------------------------------------------
DOWN-STREAM Development Team
--------------------------------------------------------------------------------
QC Team
--------------------------------------------------------------------------------
AQ Team
--------------------------------------------------------------------------------
Management, maintenance &
 Logistics
--------------------------------------------------------------------------------
             TOTAL:
--------------------------------------------------------------------------------
<PAGE>

                                    Annex 3

                                  The Project

ARTICLE 1 : Definitions
The work programme is defined in the attached document

     -----------------------------------------------------------
            Pro-APO Al Project -- Work Programme -3
     -----------------------------------------------------------

The allocation of the rooms in the GMP production facility of Eurogentec is
described in the attached document

     -----------------------------------------------------------
      (Room allocation - Proapolipoprotein Al (ApoAl project)
     -----------------------------------------------------------

ARTICLE 2 : Schedule

The schedule is defined by the gantt charts

     -----------------------------------------------------------
                 Pro-ApoAl total 06 March 2000
     -----------------------------------------------------------

and

     -----------------------------------------------------------
                         Pro-ApoAl DSP
     -----------------------------------------------------------
<PAGE>

        ---------------------------------------------------------------
                   [Pro-APO A1 Project - Work Programme - 3
        ---------------------------------------------------------------

Final work programme revised as March 6, 2000.

1   Introduction

Following the visit of 19 January 2000 of Mrs Rea and Dasseux who presented the
pro-APO Al project, there have been two technical meetings with Mrs Simon to
study in depth the production process.

The objective of this analysis was to answer two questions.  First can
Eurogentec perform the production process and his largest scale (300 litres),
and second, is it possible to deliver 300 g of pro-APO Al for end of June.

It came to the conclusion that providing some moderate scaling up, Eurogentec
should be capable of performing the production up to the delivery of purified
pro-APO A1 ready for fomulation.  To say, down to point V of the pro-APO A1Rec
flow sheet provided by Mr Simon in the February 3 meeting.  Providing the very
tight timing and the necessity to provide 300 g of product, it is impossible to
accommodate the formulation of the pro-APO Al.  Moreover, Eurogentec has no
experience in such formulation, hence it is probably more efficient that
Esperion takes care of the formulation or outsource it to a specialised
contractor.

Regarding the delivery of 300 g of purified pro-APO Al this target can be
achieved providing that the announced yield of 200 mg of purified protein per
litre of culture broth is observed and that the purification process can be
performed at the 3001 scale.

2   Technology transfer

A technology transfer phase has been designed.  It has been much compressed to
meet the June dead line.

2.1 Fermentation

The fermentation in the R&D laboratory will be performed at the 20 litres scale
that is directly scalable to 300 litres owing to our extensive experience of E.
coli processes.  The purpose of the fermentation will be (1) to master the
process developed by Dr.  Simon and (ii) to provide material for the down stream
processing (DSP).
<PAGE>

Two fermentations have been programmed with the process of Dr Simon.  The
protocol will be superstitiously reproduced in every details.  A third one will
be done if the parameterisation of the fed batch flow is more difficult than
expected.

As soon as the DSP has reproduced the process and the QC as established the
necessary assays to qualify the protein, a fermentation will be performed
according to our standard fermentation formula.  It has been improved for years
and has always been superior to what our sponsors have provided.  During our
meetings, we have expressed some concerns on the fermentation protocol used so
far which appears to us to be outdated and not usefully complex, hence with some
consistency issue.  If our standard formula yields similar amount of best
quality protein, we will propose to you to change for our simpler and more
efficient protocol.  If not, we will continue with the current method.

As soon as the fermentation protocol is implemented in the laboratory, it will
be transferred to the production unit.  Two fermentations are planned to first
confirm the scalability of the process second, to set the harvest parameters.
So far the bacterial cells were harvested as a solid paste, this is impossible
with our equipment at the 300 litres scale.  The continuous centrifuge yields
highly enriched cell suspension in buffer.  Will this buffer exchange in the
centrifuge be sufficient to go on with the process and how many cycles will be
necessary to achieve sufficient medium removal.  The cells harvested at this
stage will be directly transferred to the R&D DSP laboratory for further
processing and assessment of quality.

The first step of full-scale liquid-liquid extraction and filtrabiity of the
pro-APO Al fraction will be tested at this stage.  The purchase of two large
volume centrifuge will be necessary to run the process at the 300 litres scale.

Two more 300 litres fermentations are planned for further consistency and to
provide adequate material for the first full-scale purification, see annexed
Gantt chart (Esperion total).

At the completion of these assays, the fermentation process, harvest and
extraction will be ready for true GMP operations.

2.2  Downstream processing
<PAGE>

Starting from the cells harvested from the first fermentation, the exact process
described will be repeated at the 1 litre scale.  The columns will be scaled for
a 1 litre process as a 100 x scale down from the described process.  The flows
will be reduced accordingly.

In order to optimise the flows, a second purification will be performed at the 1
litre scale.  The flow will be increased to the usual value for the said'
chromatographic resin.  This step is crucial to be able to perform the complete
DSP within one working week.

A third purification will be performed on the same columns, possibly with the
increased flows, but at the 3 litres scale.  Dr Simon told us that the capacity
of the columns was largely superior to what was needed for his scale of
operation.  The aim of this step is to investigate the possibility of running
the GMP process at the 300 litres scale instead of 100 litres.  The final size
of the column will be set according to the result obtained at this stage.  Of
course in process control will be implemented in order to document possible
overloading of the columns.

The most delicate step of the current process is the final SP chromatography
with a pH gradient.  We could obtain only fragmentary data on that part of the
process.  So two kinds of gradient durations will be tested, 4 or 16 hours.  The
impact of the result on the duration of the DSP is pivotal.

If necessary any of these experiments will be repeated in order to obtain
consistent results.  Eurogentec can provide the material obtained during these
early development stages..  It will be appreciate that Esperion can run some
testing on the purified protein and confirms our QC results.

At this stage, the fermentation team will be growing the strain in the 300
litres fermentor and will investigate the harvest procedure.  The complete DSP
will be performed at small scale on the material fermented and harvested at
large scale in order to verify that the full scale harvest and liquid-liquid
extraction perform according to the expectation.

The sterile filtration of the PEG fraction following the liquid-liquid
extraction will be developed at this stage in close collaboration between the
fermentation and DSP teams.

Finally, two full-scale purifications will be performed in the GMP production
unit in order to validate the flow rates and column load before entering true
GMP operations.  At this stage it will be possible to give a forecast of the
production yield.
<PAGE>

The product obtained can be used for formulation or animal studies.

A second industrial chromatograph will be purchased to achieve the highest
consistency level.

2.3    Quality Control

The QC and IPC tests will be developed concomitantly with the development of
femientation and DSP.  The GMP QC team will be in charge of this development.
One supplementary technician will be engaged.  There is a trained person on the
waiting list so that this hiring should cause no hurdle.

2.3.1  QC on raw materials

The listing of the raw material currently used in the process shows that 13
compounds are not yet in our warehouse.  The testing of those for which
pharmacopoeia monographs are available will be outsourced to a licensed
laboratory.  These controls will be outsourced in order to allow the QC team to
properly adapt or develop the pro-APO Al specific controls.

We will set the specifications and QC procedures for then 5 compounds that don't
have monographs (Dextran T500, Hepes, Mops, ammonium sulfate & IPTG).  The
controls will be performed in house.

2.3.2  Fermentation IPC

These tests such as purity, identification, plasmid retention, dry weight are
adaptation of the current tests and should not cause any hurdles.

However, we would appreciate to have an end of femientation test that measures
the level of expression of the pro-APO Al.  This test will be transferred from
the laboratoiy of Dr Simon.

2.3.3  Purification IPC

Specific procedures need to be adapted for the protein assay, SDS-PAGE and IEF.

2.3.4  Quality Control on purified bulk

The following test has been planned and will be adapted or transferred from
laboratory of Dr Simon.

       1.  Protein quantification

       2.  Purity by SDS-PAGE
<PAGE>

       3.  Identity of pro-APO Al by Western blot / ELISA

       4.  Activity of pro-APO Al by RIA (availability of reagent is still
           questionable)

       5.  IEF

       6.  Endotoxins (gel clot following pre-treatment of the sample)

       7.  Residual DNA (quantitative PCR) possibly outsourced

       8.  Sterility

       9.  Purity of bulk by measurement of E.  coli contaminant (ELISA/WB)

Since the final bulk and most of the chromatographic process is performed in
urea, a specific urea removal method has to be defined.  Gel filtration on
disposable columns or dialysis will be evaluated.

3  Seeds

Due to the heavy workload caused by the transfer and adaptation of the process,
Eurogentec will probably not be capable of constructing the Master Cell Bank and
Working Cell Bank of the strain.  It is suggested that Esperion outsources these
tasks to a specialised company such as Q-one Biotech in England.

4  GMP manufacturing

The GMP manufacturing will be performed according to rules described in the
provisional "quality package" that has been given to Esperion during our first
meeting.

The annexed Gantt chart (Esperion DSP) shows the detail of the operation for one
week.  Two distinct series of operation are presented, first, the fermentation
and DSP operation performed in the fermentation hail down to the freezing of the
disrupted cells and second, the DSP operations starting from the liquid-liquid
extraction down to the sterile filtration of the bulk.  In the example shown,
the DSP operation would use material produced on the week before.

On the Monday there will be two distinct operations in the fermentation hall,
the conditioning of the fermentor for the next run and the extraction-maturation
procedure on the broken cells produced in a previous run.
<PAGE>

To reduce the risks of fermentor breakdown, both fennentors will undergo
complete service before the campaign.  The downstream processing equipment
should be trouble free.

The buffers and media will be prepared daily and used immediately.  One
additional staff will be engaged for buffer preparation and environmental
control.

The additional staff engagement was planned a few weeks later to service the
second production unit.  The construction of this unit is planned to start by
June, but at this period only external embankment works are scheduled, they
should not impact on the GMP operations.

Each batch will undergo full QC testing and will be released for use in human by
our QA officer.  The main criteria for release will be purity, endotoxins,
residual DNA and sterility.  The batches will be stored on site or forwarded to
you or to the company performing the formulation and freeze drying as you will
instruct us.

To produce 300 g of purified proApo Al protein with an announced yield of 200 mg
per litre of culture broth, 1500 litres are necessary.  Thus 5 runs should be
sufficient.  2 more runs have been planned as back up.  If all the runs perform
according to the' specifications, more protein, possibly 420 g will be
delivered.

The product will be released as discrete batches of expectedly 60 g.  A full
batch record will accompany each batch.

The batches will be sterile filtered and stored at --20(degrees)C until
delivery. We will agree on the type of containers. The shipment will be
organised in dry ice with temperature record if you wish.

5  Project Management

Mr Alain Lamproye, director of the production unit, will be the project manager.
Upon reception of your order and signature of the contract, he will organise a
Product Development Committee (PDC) in charge of the coordination of the
project.  The team leaders from R&D fermentation, R&D DSP, GMP fermentation, GMP
DSP, QC and QA are statutory members of the PDC.  At the beginning of the
project they will meet on a weekly basis.  Additional technical meetings can be
organised to address specific issues.  Mr Simon might be invited to these
meetings.

Eurogentec will appreciate that Esperion also nominates a project manager to
whom it will refer on a regular basis.  This person will be welcome to assist to
the PDC's and to stay in our facility for any period of time.  Phone conferences
can also be organised.
<PAGE>

Due to the very compact development scheme, the division of the project into
phases and milestone might be detrimental to a fast execution.  We would rather
propose to establish immediately the closest relationship with your project
manager so that we can together adapt the course of the programme to the reality
of the experimental facts.

Nevertheless, two important milestones can be identified, one at the end of the
small scale DSP operation with 300 litres fermentor material, the other at the
end of the full scale feasibility.  At this stage the expected production rate
will be ascertained.

6    Budget

6.1  Technology transfer

The cost of the technology transfer as displayed in the Esperion total Gantt
chart will be BEF 7,765,000.  This price is all-inclusive.

6.2  GMP operation

The cost of the GMP operation as described here above and in the Esperion total
and Esperion GMP Gantt chart will be BEF 29,250,000.  This price excludes the
raw materials and chromatographic media costs, those cost will not exceed USD
40,000.  Those will be invoiced separately.

Michel Thiry

6 March 2000
<PAGE>

                     Proapolipoprotein A1 (ApoA1 project)

                             Esperion Therapeutics
                             ---------------------

<TABLE>
<CAPTION>

                          Step                                        Equipment
<S>                                                        <C>
Preculture                                                          Conical flask
Fermentation (350L) : E coli                               Fermentor IF-500 (New Brunswick

Cell concentration                                          Continue centrifuge (Westfalia
                                                                        CSA119
Cell storage (-20(degrees)C)                                         Freezer - 20(degrees)C
Cell breakage                                              DynoMil D20 (glass bead miller)
Liquid/liquid extraction                                             Nalgene tank
Centrifugation                                             Centrifuge (Beckman Avanti-J20)

Filtration, 0,22 um
------------------------------------------------------------------------------------------------

1/st/ chromatographic step: Q Sepharose FF                     BioProcess (Pharmacia) nr1
(ion exchange)                                                 Column : Modulne 180 (degrees) 250
2/nd/ chromatographic step: Q Sepharose FF                     BioProcess (Pharmacia) nr2
(ion exchange)                                                 Column : Vantage 250 (degrees) 500
3/rd/ chromatographic step: Sepharose Phenyl CL4B              BioProcess (Pharmacia) nr1
(hydrophobic)                                                  Column : Modulne 350 (degrees) 500

4/th/ chromatographic step: Q Sepharose FF                     BioProcess (Pharmacia) nr2
(ion exchange)                                                  Column : Vantage 90 (degrees) 500
5/th/ chromatographic step: Chelating Sepharose FF             BioProcess (Pharmacia) nr1
 (affinity)                                                     Column : Modulne 90 (degrees) 500

6/th/ chromatographic step: SP Sepharose FF                    BioProcess (Pharmacia) nr2
(ion exchange)                                                  Column : Vantage 90 (degrees) 500

------------------------------------------------------------------------------------------------
Sterile filtration
Purified bulk aliquoting
------------------------------------------------------------------------------------------------
Purified bulk storage (-20(degrees)C)                                Freezer -20(degrees)C

<CAPTION>

                          Step                                           Operations                                 Class    Room
<S>                                             <C>                                                                 <C>     <C>
Preculture                                                                                                           10000  A01-D-05
Fermentation (350L) : E coli                                Culture: Fed-batch mode                                  10000  A01-D-04
                                                            (ApoA1 soluble expression
Cell concentration                                                 Buffer exchange                                   10000  A01-D-04

Cell storage (-20(degrees)C)                                                                                         10000  A01-D-04
Cell breakage                                                                                                        10000  A01-D-04
Liquid/liquid extraction                               PEG / Dextran extraction (16 hours at 4(degrees)C, stirring   10000  A01-D-04
Centrifugation
                                                   Centrifugation: 8000 rpm, 15 minutes -->supernatant Supernatant   10000  A01-D-04
                                                                                                          recovery
Filtration, 0,22 um                                               Supernatant clarification between chromatography   10000  A01-D-04
------------------------------------------------------------------------------------------------------------------------------------
1/st/ chromatographic step: Q Sepharose FF                                  Negative mode (flowthrough collection)   10000  A02-C-05
(ion exchange)                                                                                    Protease removal
2/nd/ chromatographic step: Q Sepharose FF                                                           Positive mode   10000  A02-C-05
(ion exchange)
3/rd/ chromatographic step: Sepharose Phenyl CL4B                                                Elution : urea 6M   10000  A02-C-05
(hydrophobic)

4/th/ chromatographic step: Q Sepharose FF                                                           Positive Mode   10000  A02-C-05
(ion exchange)
5/th/ chromatographic step: Chelating Sepharose FF                                                      Metal : Cu   10000  A02-C-05
 (affinity)                                                                             Two columns used in series
                                                                        The second one is not saturated with metal
                                                                                       (Cu removal during elution)

6/th/ chromatographic step: SP Sepharose FF                                               Deamidated forms removal   10000  A02-C-05
(ion exchange)                                                                                    Gradient elution
                                                              IEF analysis of eluted fractions - fractions pooling
                                                              ----------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
Sterile filtration                                                                                                     100   A03-B-5
Purified bulk aliquoting                                                                                               100   A03-B-5
------------------------------------------------------------------------------------------------------------------------------------
Purified bulk storage (-20(degrees)C)
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
Nom de la tache                           Duree
-------------------------------------------------------------------------------------------------------------------------------
<S>                                     <C>          <C>
Fermentation                            38 jours
----------------------------------------------------
  Fermentation 20 | 1                   2 jours
----------------------------------------------------
  Fermentation 20 | 2                   2 jours
----------------------------------------------------
  Fermentation20 | 3                    2 jours
----------------------------------------------------
  Fermentation300 | 1                   3 jours
----------------------------------------------------
  Fermentation300 | 2                   3 jours                                  GRAPHICS OMITTED
----------------------------------------------------
  Fermentation300 | 3                   3 jour
----------------------------------------------------
  Fermentation 300 | 4                  3 jours
----------------------------------------------------
Down stream processing                  44 jours
----------------------------------------------------
  repeatability 1|                      2,8 sms
----------------------------------------------------
  optimisation 1|                       1 sm
----------------------------------------------------
  process 3| + gradient (1/100)         1 sm
----------------------------------------------------
  process 31 with 300 | material        I sm
----------------------------------------------------
  Decision point                        0 jour
----------------------------------------------------
  full scale feasibility                14 jours
----------------------------------------------------
  Decision point                        0 jour
----------------------------------------------------
GMP production                          45 jours
----------------------------------------------------
  run 1                                 2 sms
----------------------------------------------------
  run 2                                 2 sms
----------------------------------------------------
  run 3                                 2 sms
----------------------------------------------------
  run 4                                 2 sms
----------------------------------------------------
  run 5                                 2 sms
----------------------------------------------------
  backup run 1                          2 sms
----------------------------------------------------
  release of the last batch             jour
----------------------------------------------------
Outsourced Cell Banking                 4 sms
----------------------------------------------------
QC operations                           89jours
----------------------------------------------------
  Raw materials controls                40 jours
----------------------------------------------------
  Development of IPC                    40 jours
----------------------------------------------------
  Development of QC on bulk             45 jours
----------------------------------------------------
  Environmental controls (GMP)          jours
----------------------------------------------------
  QC on bulks                           59 jours
----------------------------------------------------
QA operations                           112 jours
----------------------------------------------------
  Raw material specifications           29jours
----------------------------------------------------
</TABLE>
<PAGE>

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------------------
Nom de la tache                           Duree
----------------------------------------------------
<S>                                     <C>
  Review RM SOP                         17 jours
----------------------------------------------------
  Review of QC & IPC SOP                27jours
----------------------------------------------------
  Set product specifications            7 jours
----------------------------------------------------
  Review process document               8 jours
----------------------------------------------------
  Notification to MH                    0 jour
----------------------------------------------------
  Obtain clearance from MH              0 jour
----------------------------------------------------
  Review batch records                  39 jours
----------------------------------------------------
  Releases of bulks                     36 jours
-------------------------------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------------------
<S>                                     <C>
A1 project Fermentation steps
----------------------------------------
Fermentation
----------------------------------------
Fermentator set-up
----------------------------------------
Preculture inoculation
----------------------------------------
SIP Filter skid
----------------------------------------
Fermentator aviation
----------------------------------------
Fermentation (cell growth)
----------------------------------------
Induction                                                                  GRAPHICS OMITTED
----------------------------------------
  Cellular concentration
----------------------------------------
  Cell breakage
----------------------------------------
  Cell freezing
----------------------------------------
  CIP fermentor
----------------------------------------
  SIP fermentor
----------------------------------------
  CIP CU1
----------------------------------------
  SIP CU1
----------------------------------------
  CIP centrifuge Westfalia
----------------------------------------
  SIP centrifuge Wesfalia
----------------------------------------
  CIP CU2
----------------------------------------
  SIP CU2
----------------------------------------
Al project: purification steps
----------------------------------------
Downstream 100.000
----------------------------------------
  Cell thawing
----------------------------------------
  Liquid: Liquid extraction
----------------------------------------
  1/st/ Centrifugation
----------------------------------------
  Maturation
----------------------------------------
  2/nd/ Centrifugation
----------------------------------------
  Sterile filtration
----------------------------------------
Downstream 10.000
----------------------------------------
  First column (QAE (-))
----------------------------------------
     QAE (-) equilibration.
----------------------------------------
     QAE (-) load
----------------------------------------
</TABLE>
<PAGE>

<TABLE>
<S>                                     <C>
----------------------------------------
     QAE (-) elution
----------------------------------------
     QAE (-) regeneration
----------------------------------------
  Second column (QAE (+)
----------------------------------------
     QAE (+) equilibration.
----------------------------------------
     QAE (+) load
----------------------------------------
     QAE (+) elution
----------------------------------------
     QAE (+) regeneration
----------------------------------------
  Third column (HIC
----------------------------------------
     HIC Phenyl equilibration
----------------------------------------
     HIC Phenyl load
----------------------------------------
     HIC Phenyl elution
----------------------------------------
     HIC Phenyl regeneration
----------------------------------------
  Fourth column (QAE (+))
----------------------------------------
     QAE (+) equilibration.
----------------------------------------
     QAE (+) load
----------------------------------------
     QAE (+) washing
----------------------------------------
     QAE (+) elution
----------------------------------------
     QAE (+) regeneration
----------------------------------------
Fifth column (Chelate FF)
----------------------------------------
     Chelate FF equilibration.
----------------------------------------
     Chelate FF load
----------------------------------------
     Chelate FF elution
----------------------------------------
     Chelate FF regeneration
----------------------------------------
Sixth column (SP Sepharose)
----------------------------------------
     SPFF equilibration.
----------------------------------------
     SPFF load
----------------------------------------
     SPFF washing
----------------------------------------
     SPFF elution
----------------------------------------
     SPFF regeneration
----------------------------------------
     Fraction pooling
----------------------------------------
Sterile filtration
----------------------------------------
  Class 100 operations
----------------------------------------

----------------------------------------
Quality Control
----------------------------------------
  IPC analysis (IEF)
-------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>

                                    Annex 4

                                   The Price

ARTICLE 1: Definitions

     All prices are in BEF or in USD as specified and are exclusive of VAT.

ARTICLE 2: Prices

     The price of the technology transfer phase is BEF 7,765,000.

     The price of the GMP manufacturing phase is BEF 29,250,000.

     The cost of the raw materials shall not exceed USD 40,000.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]